JP2016014040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016014040A5 JP2016014040A5 JP2015166933A JP2015166933A JP2016014040A5 JP 2016014040 A5 JP2016014040 A5 JP 2016014040A5 JP 2015166933 A JP2015166933 A JP 2015166933A JP 2015166933 A JP2015166933 A JP 2015166933A JP 2016014040 A5 JP2016014040 A5 JP 2016014040A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- tapentadol
- antagonist
- opioid antagonist
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 claims description 39
- 229960005126 tapentadol Drugs 0.000 claims description 38
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims description 38
- 239000003401 opiate antagonist Substances 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 12
- -1 nalide Chemical compound 0.000 claims description 6
- JVLBPIPGETUEET-WIXLDOGYSA-O (3r,4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one Chemical compound C([N@+]1(C)[C@@H]2CC=3C4=C(C(=CC=3)O)O[C@@H]3[C@]4([C@@]2(O)CCC3=O)CC1)C1CC1 JVLBPIPGETUEET-WIXLDOGYSA-O 0.000 claims description 4
- 229960002921 methylnaltrexone Drugs 0.000 claims description 4
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 3
- 229960005297 nalmefene Drugs 0.000 claims description 3
- OHKCLOQPSLQCQR-MBPVOVBZSA-N nalmexone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(CC=C(C)C)[C@@H]3CC5=CC=C4O OHKCLOQPSLQCQR-MBPVOVBZSA-N 0.000 claims description 3
- 229950008297 nalmexone Drugs 0.000 claims description 3
- 229960004127 naloxone Drugs 0.000 claims description 3
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 3
- 229960003086 naltrexone Drugs 0.000 claims description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 3
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 claims description 2
- 229960000805 nalbuphine Drugs 0.000 claims description 2
- 208000002173 dizziness Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 4
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 4
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 4
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N (Z)-chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 2
- DKMFBWQBDIGMHM-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)-1-butanone Chemical compound C1CC(C)CCN1CCCC(=O)C1=CC=C(F)C=C1 DKMFBWQBDIGMHM-UHFFFAOYSA-N 0.000 description 2
- FEBOTPHFXYHVPL-UHFFFAOYSA-N 3-[1-[4-(4-fluorophenyl)-4-oxobutyl]-4-piperidinyl]-1H-benzimidazol-2-one Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 FEBOTPHFXYHVPL-UHFFFAOYSA-N 0.000 description 2
- RKLNONIVDFXQRX-UHFFFAOYSA-N Bromperidol Chemical compound C1CC(O)(C=2C=CC(Br)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 RKLNONIVDFXQRX-UHFFFAOYSA-N 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- LQJLLAOISDVBJM-FMKPAKJESA-N axomadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CC[C@@H](O)C2)CN(C)C)=C1 LQJLLAOISDVBJM-FMKPAKJESA-N 0.000 description 2
- 229950005531 axomadol Drugs 0.000 description 2
- 229960002507 benperidol Drugs 0.000 description 2
- 229960004037 bromperidol Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- 229960001552 chlorprothixene Drugs 0.000 description 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- 229960002419 flupentixol Drugs 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960001861 melperone Drugs 0.000 description 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 description 2
- 229940042053 methotrimeprazine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229960000938 nalorphine Drugs 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 2
- 229960002195 perazine Drugs 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002784 thioridazine Drugs 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 2
- 229960004496 zotepine Drugs 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19762508P | 2008-10-30 | 2008-10-30 | |
| US61/197,625 | 2008-10-30 | ||
| US20531209P | 2009-01-21 | 2009-01-21 | |
| US61/205,312 | 2009-01-21 | ||
| US26863009P | 2009-06-15 | 2009-06-15 | |
| US61/268,630 | 2009-06-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534509A Division JP6216489B2 (ja) | 2008-10-30 | 2009-10-29 | 新規の、効力のあるタペンタドール剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016014040A JP2016014040A (ja) | 2016-01-28 |
| JP2016014040A5 true JP2016014040A5 (https=) | 2016-03-10 |
| JP6426560B2 JP6426560B2 (ja) | 2018-11-21 |
Family
ID=42634123
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534509A Expired - Fee Related JP6216489B2 (ja) | 2008-10-30 | 2009-10-29 | 新規の、効力のあるタペンタドール剤形 |
| JP2015166933A Expired - Fee Related JP6426560B2 (ja) | 2008-10-30 | 2015-08-26 | 新規の、効力のあるタペンタドール剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534509A Expired - Fee Related JP6216489B2 (ja) | 2008-10-30 | 2009-10-29 | 新規の、効力のあるタペンタドール剤形 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9642801B2 (https=) |
| EP (1) | EP2352494B1 (https=) |
| JP (2) | JP6216489B2 (https=) |
| KR (2) | KR101806796B1 (https=) |
| CN (2) | CN104257600A (https=) |
| AU (2) | AU2009340504A1 (https=) |
| BR (1) | BRPI0921725A2 (https=) |
| CA (1) | CA2741984C (https=) |
| CL (1) | CL2011000967A1 (https=) |
| CO (1) | CO6382115A2 (https=) |
| CY (1) | CY1122269T1 (https=) |
| DK (1) | DK2352494T3 (https=) |
| EC (2) | ECSP11011016A (https=) |
| ES (1) | ES2758831T3 (https=) |
| HR (1) | HRP20191909T1 (https=) |
| HU (1) | HUE047438T2 (https=) |
| IL (2) | IL212523A0 (https=) |
| LT (1) | LT2352494T (https=) |
| MX (1) | MX2011004455A (https=) |
| NZ (1) | NZ592437A (https=) |
| PE (3) | PE20110390A1 (https=) |
| PL (1) | PL2352494T3 (https=) |
| PT (1) | PT2352494T (https=) |
| RU (2) | RU2599846C2 (https=) |
| SI (1) | SI2352494T1 (https=) |
| WO (1) | WO2010096045A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0921725A2 (pt) | 2008-10-30 | 2016-01-05 | Grüenthal GmbH | formas de dosagem potentes do tapentadol |
| BRPI1014720A2 (pt) * | 2009-04-30 | 2016-04-12 | Gruenenthal Gmbh | uso de compostos de 1-fenil-3-dimetilaminopropano para o tratamento da dor reumatoide |
| US10363251B2 (en) | 2009-07-16 | 2019-07-30 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| EP2566461A2 (de) * | 2010-05-05 | 2013-03-13 | Ratiopharm GmbH | Festes tapentadol in nicht-kristalliner form |
| CA2798884C (en) | 2010-05-10 | 2016-09-13 | Euro-Celtique S.A. | Manufacturing of active-free granules and tablets comprising the same |
| CN103002881B (zh) | 2010-05-10 | 2015-09-02 | 欧洲凯尔特公司 | 载有活性剂的颗粒与额外活性剂的组合 |
| AU2011252039B2 (en) | 2010-05-10 | 2014-06-12 | Euro-Celtique S.A. | Pharmaceutical compositions comprising hydromorphone and naloxone |
| WO2012008984A1 (en) | 2010-07-16 | 2012-01-19 | Mallinckrodt Llc | (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| EP3597628A1 (en) * | 2010-07-23 | 2020-01-22 | Grünenthal GmbH | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| WO2012051246A1 (en) * | 2010-10-12 | 2012-04-19 | Ratiopharm Gmbh | Tapentadol hydrobromide and crystalline forms thereof |
| RS56692B1 (sr) * | 2011-03-04 | 2018-03-30 | Gruenenthal Gmbh | Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol |
| KR101946790B1 (ko) | 2011-03-04 | 2019-02-13 | 그뤼넨탈 게엠베하 | 경구 투여를 위한 타펜타돌의 수성 약제학적 제형 |
| EP2736501B1 (en) * | 2011-07-29 | 2017-12-20 | Grünenthal GmbH | Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| EP2606879A1 (en) * | 2011-12-21 | 2013-06-26 | Hexal AG | Multiple unit pellet tablet formulation comprising an opioid |
| EP2872126B1 (en) * | 2012-07-16 | 2017-12-06 | Grünenthal GmbH | Pharmaceutical patch for transdermal administration of tapentadol |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| ES2846736T3 (es) * | 2013-08-14 | 2021-07-29 | Evonik Operations Gmbh | Composición de recubrimiento |
| CN103432107A (zh) * | 2013-08-20 | 2013-12-11 | 安徽省先锋制药有限公司 | 一种盐酸他喷他多对乙酰氨基酚口腔崩解片及其制备方法 |
| EP2845625A1 (en) * | 2013-09-04 | 2015-03-11 | Grünenthal GmbH | Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome |
| WO2015071380A1 (en) | 2013-11-13 | 2015-05-21 | Euro-Celtique S.A. | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CN103655523A (zh) * | 2013-12-24 | 2014-03-26 | 南京艾德凯腾生物医药有限责任公司 | 他喷他多组合物 |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3273953B1 (en) | 2015-03-27 | 2019-01-02 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
| CN109996533A (zh) | 2016-09-23 | 2019-07-09 | 格吕伦塔尔有限公司 | 用于肠胃外施用他喷他多的稳定制剂 |
| CN111346078B (zh) * | 2018-12-21 | 2022-06-10 | 宜昌人福药业有限责任公司 | 一种他喷他多或其药学上可接受的盐经鼻粘膜给药的药物组合物及其制备方法和应用 |
| WO2020252384A1 (en) * | 2019-06-14 | 2020-12-17 | Vorsanger Gary | Treatment methods utilizing oxytocin receptor agonists |
| EP3875079A1 (en) | 2020-03-02 | 2021-09-08 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| PE20230105A1 (es) | 2020-03-02 | 2023-01-25 | Gruenenthal Chemie | Forma de dosificacion que proporciona liberacion prolongada de sal de acido fosforico de tapentadol |
| PL3875077T3 (pl) | 2020-03-02 | 2024-03-11 | Grünenthal GmbH | Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu |
| DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4034758A (en) | 1975-09-08 | 1977-07-12 | Alza Corporation | Osmotic therapeutic system for administering medicament |
| US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| US5071607A (en) | 1990-01-31 | 1991-12-10 | Alza Corporatino | Method and apparatus for forming a hole in a drug dispensing device |
| US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| GB9401894D0 (en) | 1994-02-01 | 1994-03-30 | Rhone Poulenc Rorer Ltd | New compositions of matter |
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| EP0914097B1 (en) | 1996-03-12 | 2002-01-16 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
| US6103258A (en) * | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
| EP1041988A4 (en) | 1997-12-22 | 2002-03-13 | Euro Celtique Sa | METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS |
| EP1041987B1 (en) | 1997-12-22 | 2006-04-19 | Euro-Celtique S.A. | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone |
| US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
| US6765010B2 (en) | 1999-05-06 | 2004-07-20 | Pain Therapeutics, Inc. | Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
| US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
| EP2092936B1 (en) * | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20040024004A1 (en) * | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| US6559159B2 (en) | 2001-02-01 | 2003-05-06 | Research Triangle Institute | Kappa opioid receptor ligands |
| IL160222A0 (en) * | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist |
| DE10146275A1 (de) * | 2001-09-18 | 2003-04-24 | Gruenenthal Gmbh | Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10152469A1 (de) * | 2001-10-24 | 2003-06-26 | Gruenenthal Gmbh | 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung |
| HUE032656T2 (en) | 2002-04-05 | 2017-10-30 | Euro Celtique Sa | Pharmaceutical composition containing oxicodone and naloxone |
| US20050191244A1 (en) | 2002-10-25 | 2005-09-01 | Gruenenthal Gmbh | Abuse-resistant pharmaceutical dosage form |
| PT1562567T (pt) * | 2002-11-22 | 2017-08-24 | Gruenenthal Gmbh | Combinação de analgésicos selecionados e inibidores da cox-ii |
| WO2004098565A2 (en) | 2003-05-02 | 2004-11-18 | Surmodics, Inc. | Implantable controlled release bioactive agent delivery device |
| US7332142B2 (en) | 2005-06-17 | 2008-02-19 | Emcon Tehnologies Germany (Augsburg) Gmbh | Method and apparatus for bubble injection of agent into exhaust gas for use with emission abatement device |
| US20090082466A1 (en) | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
| WO2008027442A2 (en) * | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| DE102007019417A1 (de) * | 2007-04-23 | 2008-11-13 | Grünenthal GmbH | Tapentadol zur Schmerzbehandlung bei Arthrose |
| EP1985292A1 (en) | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| BRPI0921725A2 (pt) | 2008-10-30 | 2016-01-05 | Grüenthal GmbH | formas de dosagem potentes do tapentadol |
-
2009
- 2009-10-29 BR BRPI0921725A patent/BRPI0921725A2/pt not_active IP Right Cessation
- 2009-10-29 ES ES09840521T patent/ES2758831T3/es active Active
- 2009-10-29 KR KR1020177004316A patent/KR101806796B1/ko not_active Expired - Fee Related
- 2009-10-29 PL PL09840521T patent/PL2352494T3/pl unknown
- 2009-10-29 PE PE2011000943A patent/PE20110390A1/es not_active Application Discontinuation
- 2009-10-29 WO PCT/US2009/005866 patent/WO2010096045A1/en not_active Ceased
- 2009-10-29 MX MX2011004455A patent/MX2011004455A/es active IP Right Grant
- 2009-10-29 RU RU2011121513/15A patent/RU2599846C2/ru active
- 2009-10-29 HU HUE09840521A patent/HUE047438T2/hu unknown
- 2009-10-29 SI SI200932006T patent/SI2352494T1/sl unknown
- 2009-10-29 HR HRP20191909TT patent/HRP20191909T1/hr unknown
- 2009-10-29 RU RU2015154026A patent/RU2673882C1/ru active
- 2009-10-29 AU AU2009340504A patent/AU2009340504A1/en not_active Abandoned
- 2009-10-29 NZ NZ592437A patent/NZ592437A/xx not_active IP Right Cessation
- 2009-10-29 DK DK09840521T patent/DK2352494T3/da active
- 2009-10-29 PE PE2014001450A patent/PE20142368A1/es active IP Right Grant
- 2009-10-29 CN CN201410398429.0A patent/CN104257600A/zh active Pending
- 2009-10-29 EP EP09840521.0A patent/EP2352494B1/en not_active Not-in-force
- 2009-10-29 KR KR1020117012188A patent/KR101712339B1/ko not_active Expired - Fee Related
- 2009-10-29 CA CA2741984A patent/CA2741984C/en not_active Expired - Fee Related
- 2009-10-29 CN CN2009801538254A patent/CN102281876A/zh active Pending
- 2009-10-29 JP JP2011534509A patent/JP6216489B2/ja not_active Expired - Fee Related
- 2009-10-29 LT LT09840521T patent/LT2352494T/lt unknown
- 2009-10-29 PT PT98405210T patent/PT2352494T/pt unknown
- 2009-10-29 PE PE2019000022A patent/PE20190391A1/es unknown
-
2011
- 2011-04-21 US US13/091,871 patent/US9642801B2/en not_active Expired - Fee Related
- 2011-04-28 IL IL212523A patent/IL212523A0/en unknown
- 2011-04-28 CO CO11052116A patent/CO6382115A2/es not_active Application Discontinuation
- 2011-04-29 CL CL2011000967A patent/CL2011000967A1/es unknown
- 2011-04-29 EC EC2011011016A patent/ECSP11011016A/es unknown
-
2015
- 2015-08-26 JP JP2015166933A patent/JP6426560B2/ja not_active Expired - Fee Related
- 2015-12-17 AU AU2015271879A patent/AU2015271879B2/en not_active Ceased
-
2016
- 2016-12-01 IL IL249344A patent/IL249344B/en active IP Right Grant
-
2019
- 2019-10-18 EC ECSENADI201975276A patent/ECSP19075276A/es unknown
- 2019-11-07 CY CY20191101172T patent/CY1122269T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016014040A5 (https=) | ||
| RU2011121513A (ru) | Новые и эффективные лекарственные формы тапентадола | |
| US20220062276A1 (en) | Pharmaceutical compositions | |
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2011137020A5 (https=) | ||
| RU2004106619A (ru) | Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист | |
| KR20080071185A (ko) | 부프레노르핀을 포함하는 약제학적 조성물 | |
| JP2016535773A5 (https=) | ||
| AR089130A1 (es) | FORMAS DE DOSIS FARMACEUTICA QUE COMPRENDEN POLI(e-CAPROLACTONA) Y OXIDO DE POLIETILENO | |
| PT2124556E (pt) | Composições farmacêuticas | |
| EP2588085A1 (en) | Sustained release composition comprising an amine as active agent and a salt of a cyclic organic acid | |
| CN106456550A (zh) | 避免乙醇剂量倾泻的多颗粒 | |
| RU2016123972A (ru) | Применение антагониста опиоидных рецепторов с к-активностью и вортиоксетина для лечения депрессивного расстройства с меланхолическими признаками | |
| JP2013510841A5 (https=) | ||
| CN116808038A (zh) | 阿片类物质和n-酰基乙醇胺的组合 | |
| JP2017526719A5 (https=) | ||
| US20180071278A1 (en) | Anti-overingestion dosage forms | |
| US20190209540A1 (en) | Sublingual opioid formulations containing naloxone | |
| US11207330B2 (en) | Mirtazapine for use in medication overuse headache based on tension-type headache | |
| US20100048605A1 (en) | Synergistic effects of combinations of nornicotine and opioids for the treatment of pain | |
| IL273904B1 (en) | Pharmaceutical resinate compositions and methods of making and using thereof | |
| JP2020536892A5 (https=) | ||
| DK2124556T3 (en) | Pharmaceutical compositions | |
| MX2008006610A (en) | Pharmaceutical compositions |